Wells Fargo maintains Insulet at Equal-Weight, raises price target to $172 from $144

Insulet Corp (PODD) reported Q3 2026 revenue up 19% and EPS up 60%. US new customer starts were flat, while global growth was low single-digits. The company expects 2027 growth to be modestly below mid-teens due to tougher comparisons and increased competition. Free cash flow for 2026 is expected to be $275 million. PBM negotiations for 2027 are ongoing, creating some uncertainty. The company plans to launch Omnipod 6 in 2027, with features aimed at improving clinical outcomes and lifestyle fit.

Jefferies raised its price target on Insulet (PODD) to $200 from $190, citing strong Q3 2026 results. Sales grew 19.6% to $842M, beating estimates, with EPS of $1.99. The company raised full-year sales guidance to 21-22% growth. TD Cowen also raised its target to $163, maintaining a Hold rating.

Insulet (PODD) reported Q3 revenue of $842M, adjusted EPS of $1.99, and record gross margin of 74.2%. The company narrowed its 2026 revenue outlook to 21-22% growth and expects 2027 growth to be modestly below mid-teens. Insulet also announced a $1B increase to its share repurchase program and product updates, including Omnipod 6 and a type 2 diabetes system.

Insulet Corporation reported a 20% increase in its global customer base for Q3 2026, driven by growth in the Type 2 segment and international expansion. The company launched Omnipod Discover and plans Omnipod 6 for 2027, expecting growth to moderate to below mid-teens. Management approved a $1 billion share repurchase increase and anticipates stable pricing and retention. According to the company, new competitive entrants and a larger revenue base influence the conservative 2027 outlook.

Insulet (PODD) reported Q3 2026 revenue of $842.0M, up 19.6% in constant currency, exceeding guidance. Adjusted EPS rose 59.9% to $1.99. The company grew its global customer base to over 600,000, with US Omnipod revenue up 14.7% and international up 33.0%. Management expects 2027 growth to moderate due to competition and difficult comparisons. The board approved a $1B increase in share repurchase authorization, with $400M planned for Q4.

Insulet (PODD) reported Q3 2026 earnings of $1.99 per share on $842M revenue, beating estimates. Shares rose 3.06% premarket. The company raised 2026 guidance but signaled slower 2027 growth, citing innovation timing and a larger revenue base. International sales surged 31.7%, driving overall growth.